^
    Back
    Association details:
    Biomarker:APC mutation
    Cancer:Gastrointestinal Stromal Tumor
    Drug:dasatinib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Med
    Title:

    A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood

    Published date:
    07/17/2020
    Excerpt:
    This open‐label, multi‐center, and single‐arm phase II study evaluated the efficacy of dasatinib for patients with metastatic GIST who had failed imatinib and sunitinib therapy. The primary endpoint was PFS at 3 months of dasatinib therapy...APC and/or TP53 mutation was only detected in patients with PFS ≥ 3 months.
    DOI:
    10.1002/cam4.3319
    Trial ID:
    NCT02776878